<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02295020</url>
  </required_header>
  <id_info>
    <org_study_id>8627</org_study_id>
    <nct_id>NCT02295020</nct_id>
  </id_info>
  <brief_title>Effect of Bioskin Ten-7 vs. Standard Treatment on Patient Reported Outcomes and Cytokine.</brief_title>
  <acronym>Bioskin</acronym>
  <official_title>Effect of Bioskin Ten-7 vs. Standard Treatment on Patient Reported Outcomes and Cytokine.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cropper Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cropper Medical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of the study are 1.) to evaluate pain relief following the application of the
      Bioskin Ten-7 knee brace and 2.) to determine if use of the Bioskin Ten-7 knee brace is more
      effective at reducing inflammation than standard of care alone using synovial fluid cytokine
      analysis and validated outcome measures.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Once consented, the patient is assigned to either Group A or Group B. Group A patients will
      receive standard treatment only and will not be prescribed a knee brace. Group B patients
      will receive standard treatment and the Bioskin Ten-7 knee brace. On Day 0, the patient will
      be assigned to one of the 2 groups using a 1:1 assignment. VAS, WOMAC, Oxford Knee Score,
      KOOS questionnaires will be administered and a sample of the patient's synovial fluid will be
      sent to labs for cytokine and cell count analysis. All patients will record use of NSAIDs and
      for Group B, the start and end time of brace use will be recorded. All patients will return
      in 8 weeks to assess efficacy of treatment. All patients will return their diaries, complete
      the same validated outcome measures as Day 0 and undergo a repeat synovial fluid analysis.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>KOOS - Pain</measure>
    <time_frame>Week 8- Day 0</time_frame>
    <description>Value at 8 weeks - value at day 0</description>
  </primary_outcome>
  <primary_outcome>
    <measure>KOOS - Symptoms</measure>
    <time_frame>Week 8 - Day 0</time_frame>
    <description>Value at 8 weeks - value at day 0</description>
  </primary_outcome>
  <primary_outcome>
    <measure>KOOS - ADL</measure>
    <time_frame>week 8 - day 0</time_frame>
    <description>Value at 8 weeks - value at day 0</description>
  </primary_outcome>
  <primary_outcome>
    <measure>KOOS - Sport/Rec</measure>
    <time_frame>Week 8 - day 0</time_frame>
    <description>Value at 8 weeks - value at day 0</description>
  </primary_outcome>
  <primary_outcome>
    <measure>KOOS - QOL</measure>
    <time_frame>Week 8 - day 0</time_frame>
    <description>Value at 8 weeks - value at day 0</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Synovial Fluid Analysis (IL-6)</measure>
    <time_frame>Week 8 - day 0</time_frame>
    <description>Interleukine 6 in Synovial fluid analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Synovial Fluid Analysis (IL-8)</measure>
    <time_frame>Week 8 - day 0</time_frame>
    <description>Interleukine 8 in Synovial fluid analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Synovial Fluid Analysis (TNF-alpha)</measure>
    <time_frame>Week 8 - day 0</time_frame>
    <description>Tumor necrosis factor - alpha in Synovial fluid analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Synovial Fluid Analysis (MIP - 1alpha)</measure>
    <time_frame>Week 8 - day 0</time_frame>
    <description>Macrophage Inflammatory Proteins - 1alpha</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Synovial Fluid Analysis (MCP - 1)</measure>
    <time_frame>Week 8 -day 0</time_frame>
    <description>Monocyte chemotactic protein-1 - 1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Oxford Knee Score</measure>
    <time_frame>Day 0 and Week 8</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>WOMAC</measure>
    <time_frame>Day 0 and Week 8</time_frame>
    <description>assess pain, stiffness, and physical function measured by Western Ontario and McMaster universities Osteoarthritis Index</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual Analog Scale</measure>
    <time_frame>Day 0 and Week 8</time_frame>
    <description>identifies pain level</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Osteoarthritis of the Knee</condition>
  <arm_group>
    <arm_group_label>Standard Treatment Only</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group A will receive standard treatment only such as NSAIDs and injections</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Treatment plus Bioskin Ten-7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group B will receive standard treatment such as NSAIDs and injections and the Bioskin Ten-7 knee brace.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard treatment only</intervention_name>
    <description>Standard treatment such as NSAIDs and injections</description>
    <arm_group_label>Standard Treatment Only</arm_group_label>
    <arm_group_label>Standard Treatment plus Bioskin Ten-7</arm_group_label>
    <other_name>NSAIDs and injections</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Standard treatment plus Bioskin Ten-7 knee brace</intervention_name>
    <description>Standard treatment such as NSAIDs and injections plus Bioskin Ten-7 knee brace.</description>
    <arm_group_label>Standard Treatment plus Bioskin Ten-7</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female 18 years and older with primary diagnosis of Knee OA with no other knee
             diagnosis.

          -  Must have telephone access.

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vinod Dasa, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>LSUHSC-NO, Orthopaedic Department</affiliation>
  </overall_official>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 17, 2014</study_first_submitted>
  <study_first_submitted_qc>November 18, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 19, 2014</study_first_posted>
  <results_first_submitted>April 8, 2016</results_first_submitted>
  <results_first_submitted_qc>June 1, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 11, 2016</results_first_posted>
  <last_update_submitted>June 1, 2016</last_update_submitted>
  <last_update_submitted_qc>June 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 11, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Inflammatory Agents, Non-Steroidal</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Standard Treatment Only.</title>
          <description>Group A will receive standard treatment only
Standard treatment: Standard treatment such as NSAIDs and injections</description>
        </group>
        <group group_id="P2">
          <title>Standard Treatment Plus Bioskin Ten-7.</title>
          <description>Group B will receive standard treatment and the Bioskin Ten-7 knee brace.
Standard treatment: Standard treatment such as NSAIDs and injections
Standard treatment plus Bioskin Ten-7 knee brace: Standard treatment such as NSAIDs and injections plus knee brace</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Standard Treatment Only</title>
          <description>Standard treatment only such as NSAIDs and injections</description>
        </group>
        <group group_id="B2">
          <title>Standard Treatment Plus Bioskin Ten-7 Knee Brace</title>
          <description>Standard treatment such as NSAIDs and injections plus Bioskin Ten-7 knee brace.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
            <count group_id="B2" value="20"/>
            <count group_id="B3" value="40"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.4" spread="11.3"/>
                    <measurement group_id="B2" value="61.5" spread="8.8"/>
                    <measurement group_id="B3" value="59.4" spread="10.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Standard of care</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Surpatz</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NSAID</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medications</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34.2" spread="5.8"/>
                    <measurement group_id="B2" value="30.4" spread="4.3"/>
                    <measurement group_id="B3" value="32.4" spread="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>KOOS - Pain</title>
          <description>KOOS = Knee injury and Osteoarthritis Outcome Score. Pain refers to the pain sub-score.The scale is 0 to 100 where 100 indicates no problems and 0 indicates extreme problems.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37.8" spread="18.7"/>
                    <measurement group_id="B2" value="33.5" spread="20.3"/>
                    <measurement group_id="B3" value="35.6" spread="19.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>KOOS - Symptoms</title>
          <description>KOOS = Knee injury and Osteoarthritis Outcome Score. Symptoms refers to the Symptoms sub-score.The scale is 0 to 100 where 100 indicates no problems and 0 indicates extreme problems.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45.5" spread="22.4"/>
                    <measurement group_id="B2" value="35.6" spread="16.7"/>
                    <measurement group_id="B3" value="40.4" spread="20.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>KOOS - ADL</title>
          <description>KOOS = Knee injury and Osteoarthritis Outcome Score. ADL refers to the activities of daily living sub-score. The scale is 0 to 100 where 100 indicates no problems and 0 indicates extreme problems.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40.8" spread="15.6"/>
                    <measurement group_id="B2" value="37.2" spread="22.2"/>
                    <measurement group_id="B3" value="39.0" spread="19.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>KOOS - Sport/Rec</title>
          <description>KOOS = Knee injury and Osteoarthritis Outcome Score. Sport/Rec refers to the sport and recreational activities sub-score. The scale is 0 to 100 where 100 indicates no problems and 0 indicates extreme problems.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.3" spread="25.9"/>
                    <measurement group_id="B2" value="12.1" spread="17.1"/>
                    <measurement group_id="B3" value="19.8" spread="22.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>KOOS - QOL</title>
          <description>KOOS = Knee injury and Osteoarthritis Outcome Score. QOL refers to the quality of life sub-score. The scale is 0 to 100 where 100 indicates no problems and 0 indicates extreme problems.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.7" spread="19.6"/>
                    <measurement group_id="B2" value="14.4" spread="13.8"/>
                    <measurement group_id="B3" value="20.9" spread="18.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>IL-6</title>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1639" lower_limit="49.9" upper_limit="25426"/>
                    <measurement group_id="B2" value="1309" lower_limit="9.2" upper_limit="7905"/>
                    <measurement group_id="B3" value="1467.1" lower_limit="9.2" upper_limit="25426"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>IL-8</title>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="653.3" lower_limit="19.2" upper_limit="4043"/>
                    <measurement group_id="B2" value="486.5" lower_limit="8.9" upper_limit="7802"/>
                    <measurement group_id="B3" value="643.0" lower_limit="8.9" upper_limit="7802"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>TNF-alpha</title>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="108.1" lower_limit="7.7" upper_limit="1079"/>
                    <measurement group_id="B2" value="104.8" lower_limit="2.1" upper_limit="436.8"/>
                    <measurement group_id="B3" value="108.1" lower_limit="2.1" upper_limit="1079"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>MIP-1alpha</title>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="255.5" lower_limit="1.2" upper_limit="24590"/>
                    <measurement group_id="B2" value="162.2" lower_limit="4.2" upper_limit="2069"/>
                    <measurement group_id="B3" value="250.8" lower_limit="1.2" upper_limit="24590"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>MCP-1</title>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8664" lower_limit="1233" upper_limit="24831"/>
                    <measurement group_id="B2" value="10944" lower_limit="876.7" upper_limit="21443"/>
                    <measurement group_id="B3" value="10188" lower_limit="876.7" upper_limit="24831"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>KOOS - Pain</title>
        <description>Value at 8 weeks - value at day 0</description>
        <time_frame>Week 8- Day 0</time_frame>
        <population>Discrepancies between participants flow chart and number of participants analyzed is due to patients not filling out the survey.</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Treatment Only</title>
            <description>Standard treatment only such as NSAIDs and injections.</description>
          </group>
          <group group_id="O2">
            <title>Standard Treatment Plus Bioskin Ten-7 Knee Brace</title>
            <description>Standard treatment such as NSAIDs and injections plus Bioskin Ten-7 knee brace.</description>
          </group>
        </group_list>
        <measure>
          <title>KOOS - Pain</title>
          <description>Value at 8 weeks - value at day 0</description>
          <population>Discrepancies between participants flow chart and number of participants analyzed is due to patients not filling out the survey.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.6" lower_limit="8.4" upper_limit="26.8"/>
                    <measurement group_id="O2" value="9.1" lower_limit="0.2" upper_limit="18.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.181</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>KOOS - Symptoms</title>
        <description>Value at 8 weeks - value at day 0</description>
        <time_frame>Week 8 - Day 0</time_frame>
        <population>Discrepancies between participants flow chart and number of participants analyzed is due to patients not filling out the survey.</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Treatment Only.</title>
            <description>Standard treatment only such as NSAIDs and injections.</description>
          </group>
          <group group_id="O2">
            <title>Standard Treatment Plus Bioskin Ten-7 Knee Brace</title>
            <description>Standard treatment such as NSAIDs and injections plus Bioskin Ten-7 knee brace.</description>
          </group>
        </group_list>
        <measure>
          <title>KOOS - Symptoms</title>
          <description>Value at 8 weeks - value at day 0</description>
          <population>Discrepancies between participants flow chart and number of participants analyzed is due to patients not filling out the survey.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.6" lower_limit="1.7" upper_limit="19.5"/>
                    <measurement group_id="O2" value="3.2" lower_limit="-5.4" upper_limit="11.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.232</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>KOOS - ADL</title>
        <description>Value at 8 weeks - value at day 0</description>
        <time_frame>week 8 - day 0</time_frame>
        <population>Discrepancies between participants flow chart and number of participants analyzed is due to patients not filling out the survey.</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Treatment Only</title>
            <description>Standard treatment only such as NSAIDs and injections</description>
          </group>
          <group group_id="O2">
            <title>Standard Treatment Plus Bioskin Ten-7 Knee Brace</title>
            <description>Standard treatment such as NSAIDs and injections plus Bioskin Ten-7 knee brace.</description>
          </group>
        </group_list>
        <measure>
          <title>KOOS - ADL</title>
          <description>Value at 8 weeks - value at day 0</description>
          <population>Discrepancies between participants flow chart and number of participants analyzed is due to patients not filling out the survey.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.3" lower_limit="7.4" upper_limit="23.2"/>
                    <measurement group_id="O2" value="9.8" lower_limit="2.1" upper_limit="17.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.311</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>KOOS - Sport/Rec</title>
        <description>Value at 8 weeks - value at day 0</description>
        <time_frame>Week 8 - day 0</time_frame>
        <population>Discrepancies between participants flow chart and number of participants analyzed is due to patients not filling out the survey.</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Treatment Only</title>
            <description>Standard treatment only such as NSAIDs and injections</description>
          </group>
          <group group_id="O2">
            <title>Standard Treatment Plus Bioskin Ten-7 Knee Brace</title>
            <description>Standard treatment such as NSAIDs and injections plus Bioskin Ten-7 knee brace</description>
          </group>
        </group_list>
        <measure>
          <title>KOOS - Sport/Rec</title>
          <description>Value at 8 weeks - value at day 0</description>
          <population>Discrepancies between participants flow chart and number of participants analyzed is due to patients not filling out the survey.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.8" lower_limit="-3.5" upper_limit="31.0"/>
                    <measurement group_id="O2" value="9.6" lower_limit="-7.6" upper_limit="26.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>KOOS - QOL</title>
        <description>Value at 8 weeks - value at day 0</description>
        <time_frame>Week 8 - day 0</time_frame>
        <population>Discrepancies between participants flow chart and number of participants analyzed is due to patients not filling out the survey.</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Treatment Only</title>
            <description>Standard treatment only such as NSAIDs and injections</description>
          </group>
          <group group_id="O2">
            <title>Standard Treatment Plus Bioskin Ten-7 Knee Brace</title>
            <description>Standard treatment such as NSAIDs and injections plus Bioskin Ten-7 knee brace</description>
          </group>
        </group_list>
        <measure>
          <title>KOOS - QOL</title>
          <description>Value at 8 weeks - value at day 0</description>
          <population>Discrepancies between participants flow chart and number of participants analyzed is due to patients not filling out the survey.</population>
          <units>pg/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.0" lower_limit="0.2" upper_limit="21.8"/>
                    <measurement group_id="O2" value="5.4" lower_limit="-4.7" upper_limit="15.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.449</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Synovial Fluid Analysis (IL-6)</title>
        <description>Interleukine 6 in Synovial fluid analysis</description>
        <time_frame>Week 8 - day 0</time_frame>
        <population>Discrepancies between participants flow chart and number of participants analyzed is due to either synovial fluid not present in the knee or not sufficient to be analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Treatment Only</title>
            <description>Standard treatment only such as NSAIDs and injections.</description>
          </group>
          <group group_id="O2">
            <title>Standard Treatment Plus Bioskin Ten-7 Knee Brace</title>
            <description>Standard treatment such as NSAIDs and injections plus Bioskin Ten-7 knee brace</description>
          </group>
        </group_list>
        <measure>
          <title>Synovial Fluid Analysis (IL-6)</title>
          <description>Interleukine 6 in Synovial fluid analysis</description>
          <population>Discrepancies between participants flow chart and number of participants analyzed is due to either synovial fluid not present in the knee or not sufficient to be analyzed.</population>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-453.8" lower_limit="-19670" upper_limit="18168"/>
                    <measurement group_id="O2" value="-1055" lower_limit="-7483" upper_limit="10399"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.860</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Synovial Fluid Analysis (IL-8)</title>
        <description>Interleukine 8 in Synovial fluid analysis</description>
        <time_frame>Week 8 - day 0</time_frame>
        <population>Discrepancies between participants flow chart and number of participants analyzed is due to either synovial fluid not present in the knee or not sufficient to be analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Treatment Only</title>
            <description>Standard treatment only such as NSAIDs and injections</description>
          </group>
          <group group_id="O2">
            <title>Standard Treatment Plus Bioskin Ten-7 Knee Brace</title>
            <description>Standard treatment such as NSAIDs and injections plus knee Bioskin Ten-7 knee brace</description>
          </group>
        </group_list>
        <measure>
          <title>Synovial Fluid Analysis (IL-8)</title>
          <description>Interleukine 8 in Synovial fluid analysis</description>
          <population>Discrepancies between participants flow chart and number of participants analyzed is due to either synovial fluid not present in the knee or not sufficient to be analyzed.</population>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-379.8" lower_limit="-2875" upper_limit="6878"/>
                    <measurement group_id="O2" value="-488.9" lower_limit="-3542" upper_limit="4906"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.735</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Synovial Fluid Analysis (TNF-alpha)</title>
        <description>Tumor necrosis factor - alpha in Synovial fluid analysis</description>
        <time_frame>Week 8 - day 0</time_frame>
        <population>Discrepancies between participants flow chart and number of participants analyzed is due to either synovial fluid not present in the knee or not sufficient to be analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Treatment Only</title>
            <description>Standard treatment only such as NSAIDs and injections</description>
          </group>
          <group group_id="O2">
            <title>Standard Treatment Plus Bioskin Ten-7 Knee Brace</title>
            <description>Standard treatment such as NSAIDs and injections plus Bioskin Ten-7 knee brace</description>
          </group>
        </group_list>
        <measure>
          <title>Synovial Fluid Analysis (TNF-alpha)</title>
          <description>Tumor necrosis factor - alpha in Synovial fluid analysis</description>
          <population>Discrepancies between participants flow chart and number of participants analyzed is due to either synovial fluid not present in the knee or not sufficient to be analyzed.</population>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-97.4" lower_limit="-242.3" upper_limit="172.4"/>
                    <measurement group_id="O2" value="-51.7" lower_limit="-430.0" upper_limit="280.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.479</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Synovial Fluid Analysis (MIP - 1alpha)</title>
        <description>Macrophage Inflammatory Proteins - 1alpha</description>
        <time_frame>Week 8 - day 0</time_frame>
        <population>Discrepancies between participants flow chart and number of participants analyzed is due to either synovial fluid not present in the knee or not sufficient to be analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Treatment Only</title>
            <description>Standard treatment only such as NSAIDs and injections</description>
          </group>
          <group group_id="O2">
            <title>Standard Treatment Plus Bioskin Ten-7 Knee Brace</title>
            <description>Standard treatment such as NSAIDs and injections plus Bioskin Ten-7 knee brace.</description>
          </group>
        </group_list>
        <measure>
          <title>Synovial Fluid Analysis (MIP - 1alpha)</title>
          <description>Macrophage Inflammatory Proteins - 1alpha</description>
          <population>Discrepancies between participants flow chart and number of participants analyzed is due to either synovial fluid not present in the knee or not sufficient to be analyzed.</population>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-246.7" lower_limit="-821.2" upper_limit="575.2"/>
                    <measurement group_id="O2" value="-49.8" lower_limit="-756.6" upper_limit="1715"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.323</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Synovial Fluid Analysis (MCP - 1)</title>
        <description>Monocyte chemotactic protein-1 - 1</description>
        <time_frame>Week 8 -day 0</time_frame>
        <population>Discrepancies between participants flow chart and number of participants analyzed is due to either synovial fluid not present in the knee or not sufficient to be analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Treatment Only</title>
            <description>Standard treatment only such as NSAIDs and injections</description>
          </group>
          <group group_id="O2">
            <title>Standard Treatment Plus Bioskin Ten-7 Knee Brace</title>
            <description>Standard treatment such as NSAIDs and injections plus Bioskin Ten-7 knee brace</description>
          </group>
        </group_list>
        <measure>
          <title>Synovial Fluid Analysis (MCP - 1)</title>
          <description>Monocyte chemotactic protein-1 - 1</description>
          <population>Discrepancies between participants flow chart and number of participants analyzed is due to either synovial fluid not present in the knee or not sufficient to be analyzed.</population>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7170" lower_limit="-14933" upper_limit="17960"/>
                    <measurement group_id="O2" value="-4890" lower_limit="-15989" upper_limit="17432"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.878</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Oxford Knee Score</title>
        <time_frame>Day 0 and Week 8</time_frame>
        <population>The outcome was not measured as KOOS was measured as the only patient reported outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A</title>
            <description>Group A will receive standard treatment only
Standard treatment: Standard treatment such as NSAIDs and injections</description>
          </group>
          <group group_id="O2">
            <title>Group B</title>
            <description>Group B will receive standard treatment and the Bioskin Ten-7 knee brace.
Standard treatment: Standard treatment such as NSAIDs and injections
Standard treatment plus Bioskin Ten-7 knee brace: Standard treatment such as NSAIDs and injections plus knee brace</description>
          </group>
        </group_list>
        <measure>
          <title>Oxford Knee Score</title>
          <population>The outcome was not measured as KOOS was measured as the only patient reported outcome.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>WOMAC</title>
        <description>assess pain, stiffness, and physical function measured by Western Ontario and McMaster universities Osteoarthritis Index</description>
        <time_frame>Day 0 and Week 8</time_frame>
        <population>The outcome was not measured as KOOS was measured as the only patient reported outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A</title>
            <description>Group A will receive standard treatment only
Standard treatment: Standard treatment such as NSAIDs and injections</description>
          </group>
          <group group_id="O2">
            <title>Group B</title>
            <description>Group B will receive standard treatment and the Bioskin Ten-7 knee brace.
Standard treatment: Standard treatment such as NSAIDs and injections
Standard treatment plus Bioskin Ten-7 knee brace: Standard treatment such as NSAIDs and injections plus knee brace</description>
          </group>
        </group_list>
        <measure>
          <title>WOMAC</title>
          <description>assess pain, stiffness, and physical function measured by Western Ontario and McMaster universities Osteoarthritis Index</description>
          <population>The outcome was not measured as KOOS was measured as the only patient reported outcome.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Visual Analog Scale</title>
        <description>identifies pain level</description>
        <time_frame>Day 0 and Week 8</time_frame>
        <population>The outcome was not measured as KOOS was measured as the only patient reported outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A</title>
            <description>Group A will receive standard treatment only
Standard treatment: Standard treatment such as NSAIDs and injections</description>
          </group>
          <group group_id="O2">
            <title>Group B</title>
            <description>Group B will receive standard treatment and the Bioskin Ten-7 knee brace.
Standard treatment: Standard treatment such as NSAIDs and injections
Standard treatment plus Bioskin Ten-7 knee brace: Standard treatment such as NSAIDs and injections plus knee brace</description>
          </group>
        </group_list>
        <measure>
          <title>Visual Analog Scale</title>
          <description>identifies pain level</description>
          <population>The outcome was not measured as KOOS was measured as the only patient reported outcome.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Group A</title>
          <description>Group A will receive standard treatment only
Standard treatment: Standard treatment such as NSAIDs and injections</description>
        </group>
        <group group_id="E2">
          <title>Group B</title>
          <description>Group B will receive standard treatment and the Bioskin Ten-7 knee brace.
Standard treatment: Standard treatment such as NSAIDs and injections
Standard treatment plus Bioskin Ten-7 knee brace: Standard treatment such as NSAIDs and injections plus knee brace</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>CVA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Vinod Dasa</name_or_title>
      <organization>LSUHSC-NO -Orthopaedic Department</organization>
      <phone>(504) 412-1700</phone>
      <email>vdasa@lsuhsc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

